Verve Therapeutics (VERV) Revenue & Revenue Breakdown
Verve Therapeutics Revenue Highlights
Latest Revenue (Y)
$32.33M
Latest Revenue (Q)
$6.87M
Verve Therapeutics Revenue by Period
Verve Therapeutics Revenue by Year
Date | Revenue | Change |
---|---|---|
2024-12-31 | $32.33M | 174.98% |
2023-12-31 | $11.76M | 505.77% |
2022-12-31 | $1.94M | 100.00% |
2021-12-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2019-12-31 | - | - |
Verve Therapeutics generated $32.33M in revenue during NA 2024, up 174.98% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Verve Therapeutics Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-09-30 | $6.87M | 2.59% |
2024-06-30 | $6.69M | 17.51% |
2024-03-31 | $5.70M | 10.71% |
2023-12-31 | $5.14M | 65.03% |
2023-09-30 | $3.12M | 48.92% |
2023-06-30 | $2.09M | 49.07% |
2023-03-31 | $1.40M | 38.74% |
2022-12-31 | $1.01M | 8.93% |
2022-09-30 | $929.00K | 100.00% |
2022-06-30 | - | 100.00% |
2022-03-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2021-09-30 | - | 100.00% |
2021-06-30 | - | 100.00% |
2021-03-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2020-09-30 | - | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | - |
Verve Therapeutics generated $6.87M in revenue during Q3 2024, up 2.59% compared to the previous quarter, and up 328.00% compared to the same period a year ago.
Verve Therapeutics Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
BPMC | Blueprint Medicines | $508.82M | $128.18M |
ADPT | Adaptive Bio | $178.96M | $46.44M |
CRSP | CRISPR Therapeutics | $37.31M | $602.00K |
VERV | Verve Therapeutics | $32.33M | $6.87M |
RLAY | Relay Therapeutics | $10.01M | - |
IPSC | Century Therapeutics | $6.59M | $791.00K |
PRME | Prime Medicine | $2.98M | $39.31M |
NTLA | Intellia Therapeutics | - | $9.11M |
EDIT | Editas Medicine | - | - |
SANA | Sana Bio | - | - |
CRBU | Caribou Biosciences | - | $3.46M |
BEAM | Beam Therapeutics | - | $14.27M |